Karin Conde-Knape
Karin Conde-Knape is the vice president of Novo Nordisk, the pharmaceutical company behind Wegovy and Ozempic, and she has spoken out about the challenges patients face in maintaining weight loss after discontinuing these medications. Her work focuses on the need for effective long-term solutions in obesity treatment and the physiological limits of current therapies.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Brazil | 2 | 6.50 | 0.14% | +0% | 211,049,527 | 299,999 | $1,500,000 | 2,132$ |
| Totals | 2 | 211,049,527 | 299,999 | $1,500,000 | 2,132$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Brazil:
Karin Conde-Knape is the vice president of Novo Nordisk, the manufacturer of Wegovy and Ozempic.
7
Brazil:
Karin Conde-Knape is the vice president of Novo Nordisk and explains the challenges of maintaining weight loss after stopping medication.
6